Skip to content

Efficacy of Angiographic Embolization vs Non-embolization of Moderate/Poor Vascularized Vertebral Metastases on Intraoperative Bleeding During Surgery Decompression and Vertebral Stabilization.

Efficacy of Angiographic Embolization vs Non-embolization of Moderate/Poor Vascularized Vertebral Metastases on Intraoperative Bleeding During Surgery Decompression and Vertebral Stabilization. Randomized Controlled Observer- Blinded

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03853434
Acronym
Embart
Enrollment
4
Registered
2019-02-25
Start date
2019-03-01
Completion date
2025-08-30
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Loss, Early Goal Directed Therapy, Embolization, Therapeutic, Spine Metastasis

Keywords

embolization, blood loss, Early Goal Directed Therapy, spine metastasis

Brief summary

Although angiographic embolization has been introduced for preoperative management of spine metastases in 1975 and is suggested today by many authors in the management of such pathologies, it needs to be confirmed by RCT. It is a minimally invasive procedure, not free from complications. The recent meta-analyzes, due to the limited number of patients included are not exhaustive about the effectiveness of embolization in the reduction of the intraoperative bleeding, especially in the context of poor / moderate metastasis vascularization. We want to evaluate the efficacy of preoperative angiographic embolization of intermediate / poor vascularized spine metastases in reducing intraoperative blood loss during excision surgery.

Interventions

PROCEDUREEmbolization

Angiographic embolization

Sponsors

Istituto Ortopedico Rizzoli
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male, Female aged 18 years and 75 years * prognosis \>6 months (Tokuhashi score ≤ 11) * patients with lesions with moderate vascularization (grade 2) * time between embolization and intervention \>/= 48-72 h

Exclusion criteria

* congenital and iatrogenic hemocoagulative disorders (PT INR\> 1.5, aPTT ratio\> 1.25 with documented coagulation factor deficiency, PLT \< 80,000 / microL or known coagulation pathologies); * renal failure (creatinine ≥ 1.2); * MDC iodized allergy; * pregnancy / lactation; * chronic ischemic heart disease; * precluded arterial access by angiography; * indication to emergency surgery; * time between embolization and surgery\> 72 h; * refusal by the patient.

Design outcomes

Primary

MeasureTime frameDescription
Intraoperative blood lossduring procedurevolume (ml) of intraoperative blood loss volume aspirated from operative field (ml) + differential weight gauze at the end of surgery - dry gauze weight with 1g blood conversion = 0.948ml

Secondary

MeasureTime frame
Concentration of Hemoglobin pre / post-operative24 hours
volume of transfused blood (ml)intraoperatively
Correlation between primary tumor and vascularizationduring angiographic procedure
correlation between the type of primary tumor and blood losses24 hours
technical evaluation of the final result of embolization (total - 100%, subtotal 90-80% and partial 70-50%) in relation to blood lossesduring angiographic procedure
evaluation of operative time, from incision to end of sutureduring procedure
incidence of complications related to transfusions;during hospitalization
duration of the hospitalization in ICUduring hospitalization

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026